免疫抑制薬の世界市場2020-2030

【英語タイトル】Immunosuppressive Drugs Market Report 2020-2030

visiongainが出版した調査資料(VGA20DE022)・商品コード:VGA20DE022
・発行会社(調査会社):visiongain
・発行日:2020年9月
・ページ数:413
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)USD5,850 ⇒換算¥608,400見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,099 ⇒換算¥946,296見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 4 segmentations of the Immunosuppressive Drugs Market, with forecasts for 5 Drug Classes, 5 Applications, 2 Route of Administrations Type, & 3 Distribution Channels and each forecasted at a global and regional level.

By Drug Class
• Antibodies
• Calcineurin Inhibitor
• mTOR Inhibitor
• Corticosteroids
• Others
By Application
• Autoimmune Diseases
• Rheumatoid Arthritis
• Multiple Sclerosis
• Psoriasis
• Crohn’s Disease
• Others
• Organ Transplant
By Route of Administration
• Oral Drugs
• Intravenous Drugs
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 16 leading national markets:
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• Saudi Arabia
• South Africa
• Rest of Middle East and Africa
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

【レポートの目次】

1. Report Overview
1.1. Introduction
1.1.1. What are Immunosuppressive Drugs?
1.1.2. Side Effects of Immunosuppressive Drugs?
1.1.3. What are Autoimmune Diseases?
1.1.4. What is Transplantation
1.1.5. What is Organ Rejection?
1.1.6. Immunosuppressive Drugs for Organ Transplant
1.1.7. Types of Immunosuppressive Drugs
1.2. Global Immunosuppressive Drugs Market Segmentation
1.3. Why You Should Read This Report
1.4. What This Report Delivers
1.5. Key Questions Answered By This Analytical Report Include:
1.6. Who is This Report For?
1.7. Methodology
1.7.1. COVID-19 Impact: Recovery Scenarios
1.7.2. Market Evaluation & Forecasting Methodology
1.7.3. Market Size Estimation
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Visiongain Reports
1.10. About Visiongain
2. Executive Summary of the Immunosuppressive Drugs Market
3. Market Overview of the Immunosuppressive Drugs Market
3.1. Market Dynamics
3.1.1. Market Drivers
3.1.1.1. Increasing Prevalence of Autoimmune Diseases
3.1.1.2. Rising Number of Organ Transplant Procedures
3.1.1.3. Launch of New Immunosuppressive Drugs
3.1.2. Market Restraints
3.1.2.1. Adverse-Effects and Risks of Immunosuppressive Drugs
3.1.2.2. High Cost of Immunosuppressant Drugs
3.1.2.3. Product Recall
3.1.3. Market Opportunities
3.1.3.1. Large Amount of R&D Investment by Pharmaceutical Companies
3.1.3.2. Government and NGO’s Initiatives for Organ Donation Awareness Programmes
3.1.3.3. Presence of Reimbursement Policies for Immunosuppressive Drugs
3.1.4. Market Challenges
3.1.4.1. Transplant Rejection
3.1.4.2. Shortage of Organ Donors
3.1.5. SWOT Analysis
3.1.5.1. Strengths
3.1.5.1.1. Promising Candidates in R&D
3.1.5.1.2. Unmet Clinical Need
3.1.5.2. Weaknesses
3.1.5.2.1. High Cost of Immunosuppressive Drugs
3.1.5.2.2. Generic Drugs Competition
3.1.5.3. Opportunities
3.1.5.3.1. Increasing Mergers & Acquisitions and Collaborations
3.1.5.3.2. Large Amount of R&D Investment
3.1.5.4. Threats
3.1.5.4.1. Ethical and Cultural Issues
3.1.6. Porter’s Five Forces Analysis
3.1.6.1. Competitive Rivalry
3.1.6.2. Supplier Power
3.1.6.3. Buyer Power
3.1.6.4. Threat of Substitution
3.1.6.5. Threat of New Entry
3.1.7. PEST Analysis
3.1.7.1. Political Issues: Stringent Government Regulations
3.1.7.2. Economic Pressures Raise Demand for Cost Effective Drugs
3.1.7.3. Social Factors: Increase of Disposable Income
3.1.7.4. Technological Factors: Adoption of High-end Technologies by Pharmaceutical and Biotechnology Companies
4. Global Immunosuppressive Drugs Market Size Forecast 2020-2030 by Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Global Immunosuppressive Drugs Market: COVID-19 Recovery Forecasts (V,U, W, L) 2020-2030
4.2.1. “V” shaped Recovery – Rapid Decline – Sharp Borrow -Rapid Recovery
4.2.2. “U” Shaped Recovery -Rapid Decline Early Then Slow – Gradual at the Bottom – Slow Recovery at First – Faster Recovery Later On
4.2.3. “W” Shaped Recovery -Rapid Decline – Rapid Recovery- Return of Virus – Another Sharp Decline -Recovery
4.2.4. “L” Shaped Recovery – Rapid Decline – Then Slow Growth
4.3. Antibodies
4.3.1. Significantly decreased the occurrence of episodes of acute rejection
4.4. Calcineurin Inhibitor
4.4.1. Growing adoption for the treatment of patients with organ transplant
4.5. mTOR Inhibitor
4.5.1. Some of the commonly used mTOR inhibitor drugs are rapamycin, sirolimus, temsirolimus, and everolimus
4.6. Corticosteroids
4.6.1. Effectiveness in a wide range of immune and inflammatory conditions
4.7. Other Drug Classes
4.7.1. Rising investment in R&D by pharmaceutical and biopharmaceutical companies boosts the segment growth
5. Global Immunosuppressive Drugs Market Size Forecast 2020-2030 by Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.2. Autoimmune Diseases
5.2.1. Rising adoption of biologics for the treatment of autoimmune diseases
5.2.2. Rheumatoid Arthritis
5.2.2.1. Prevalence of rheumatoid arthritis is the high in developed countries
5.2.3. Multiple Sclerosis
5.2.3.1. Immunosuppressive drugs are most successful in stages of MS with an inflammatory component
5.2.4. Psoriasis
5.2.4.1. Patients with moderate-to-severe psoriasis are commonly treated with systemic immunosuppressants
5.2.5. Crohn’s Disease
5.2.5.1. Some common immunosuppressive drugs used for the treatment of Crohn’s disease are azathioprine (Imuran), mercaptopurine (Purinethol), cyclosporine (Gengraf, Neoral, Sandimmune), and methotrexate
5.2.6. Other Autoimmune Diseases
5.2.6.1. Rising incidence of other autoimmune diseases projected to boost the segment growth
5.3. Organ Transplant
5.3.1. A large number of transplantation procedures were reported in developed regions such as the U.S., U.K., Germany, and France
6. Global Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 by Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Oral Drugs
6.1.1.1. The largest revenue grossing segment in 2019
6.1.2. Intravenous Drugs
6.1.2.1. Mounting adoption for the treatment of patients with organ transplant
7. Global Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 by Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospital Pharmacies
7.1.1.1. Accounted for the largest revenue share in 2019
7.1.2. Retail Pharmacies
7.1.2.1. One of the most preferred channel of distribution
7.1.3. Online Pharmacies
7.1.3.1. Provide better pricing, with increased access, convenience, and greater privacy for users.
8. Immunosuppressive Drugs: R&D Pipeline Analysis, 2020
8.1. R&D Pipeline Overview
8.1.1. Cosentyx (secukinumab)
8.1.1.1. A fully human injectable monoclonal antibody
8.1.2. RINVOQ (upadacitinib)
8.1.2.1. It is an investigational oral JAK1-selective inhibitor
8.1.3. SKYRIZI (risankizumab)
8.1.3.1. EC granted marketing authorization for SKYRIZI for moderate to severe plaque psoriasis
8.1.4. RG7845 (GDC-0853)
8.1.4.1. A novel tyrosine kinase (BTK) inhibitor
8.1.5. RG7413 (etrolizumab)
8.1.5.1. Clinical trials are underway to test etrolizumab in ulcerative colitis and Crohn’s disease
8.1.6. Benlysta + Rituxan
8.1.6.1. Clinical study to investigates Benlysta in combination with rituximab in adult patients with SLE
8.1.7. STELARA (ustekinumab)
8.1.7.1. Showed positive outcomes as maintenance therapy in adults patients with moderate to severe ulcerative colitis
8.1.8. TREMFYA (guselkumab)
8.1.8.1. New clinical study data from two Phase III trials
8.1.9. OTEZLA (apremilast)
8.1.9.1. Positive results from the Phase III trial
8.1.10. NULOJIX (belatacept)
8.1.10.1. Can help patients with kidney transplants safely and effectively without the long-term negative side effects
9. North America Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Immunosuppressive Drugs Market Size and Forecast by Country
9.2.1. The Largest Revenue Grossing Region
9.3. North America Immunosuppressive Drugs Market Size and Forecast by Drug Class
9.3.1. Antibodies Sub-Segment Will Dominate The Market
9.4. North America Immunosuppressive Drugs Market Size and Forecast by Application
9.4.1. Organ Transplant Segment Will Witness Fastest Growth Rate
9.5. North America Immunosuppressive Drugs Market Size and Forecast by Route of Administration
9.5.1. Increasing Number of Approvals For Oral Drugs
9.6. North America Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
9.6.1. Online Pharmacies Segment is Anticipated to Witness Highest CAGR
9.7. U.S. Immunosuppressive Drugs Market
9.7.1. Presence of Leading Vendors
9.7.2. Rise in the Number of Drug Approvals
9.8. Canada Immunosuppressive Drugs Market
9.8.1. High Investment in Drug R&D
9.8.2. Growing Number of Organ Transplant Procedures
10. Europe Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Immunosuppressive Drugs Market Size and Forecast by Country
10.2.1. The Second Largest Regional Market
10.3. Europe Immunosuppressive Drugs Market Size and Forecast by Drug Class
10.3.1. Calcineurin Inhibitor Segment Expected to Grow at Lucrative Rate
10.4. Europe Immunosuppressive Drugs Market Size and Forecast by Application
10.4.1. Easy Access to Advanced Immunosuppressive Drugs for the Treatment of Autoimmune Diseases
10.5. Europe Immunosuppressive Drugs Market Size and Forecast by Route of Administration
10.5.1. High Adoption of Oral Drugs
10.6. Europe Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
10.6.1. Growing Preference for Online Pharmacies
10.7. UK Immunosuppressive Drugs Market
10.7.1. A Hub for Advanced Drugs Development and Production
10.7.2. Increasing Prevalence of Autoimmune Diseases
10.8. Germany Immunosuppressive Drugs Market
10.8.1. Strong Funding for Healthcare
10.8.2. Universal Health Systems
10.9. France Immunosuppressive Drugs Market
10.9.1. Increasing Number of Organ Transplant Procedures
10.9.2. High Quality Renowned Medical Care With Innovation
10.10. Italy Immunosuppressive Drugs Market
10.10.1. Disinvestment, Delocalization, and Restructuring of Italian Pharmaceutical Companies
10.10.2. A Large Pharmaceutical Manufacturing Hub
10.11. Spain Immunosuppressive Drugs Market
10.11.1. Presence of Innovation Infrastructure and Government Funding
10.11.2. Availability of Highly Skilled Workforce
10.12. Russia Immunosuppressive Drugs Market
10.12.1. An Attractive Market for Any Industry Looking to Expand Within the Country
10.12.2. Government Support for Development of the Healthcare Sector
10.13. Rest of Europe Immunosuppressive Drugs Market
10.13.1. The EU Action Plan on the Organ Donation and Transplantation
10.13.2. Rising Incidences of Autoimmune Diseases
11. Asia Pacific Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Country
11.2.1. Asia Pacific market expected to grow at fastest rate
11.3. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Drug Class
11.3.1. mTOR Inhibitor segment projected to grow at significant CAGR during 2020-2030
11.4. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Application
11.4.1. Rising incidence of organ failure and autoimmune diseases in Asia Pacific
11.5. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Route of Administration
11.5.1. Rising adoption of injectable drugs
11.6. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
11.6.1. Rapidly developing economies, skilled workers, and technological innovation
11.7. Japan Immunosuppressive Drugs Market
11.7.1. Presence of Leading Pharmaceutical Companies
11.7.2. High Investment in R&D
11.8. China Immunosuppressive Drugs Market
11.8.1. Government Support to Strengthen the Healthcare Infrastructure
11.8.2. Presence of Large Geriatric Population
11.9. India Immunosuppressive Drugs Market
11.9.1. Availability of Large Trained Workforce
11.9.2. Growing Technical Capabilities
11.10. Australia Immunosuppressive Drugs Market
11.10.1. Australia Has a Rich Research Environment Coupled with Highly Experienced Researchers and Professionals
11.10.2. Excellent Health Care Infrastructure
11.11. Rest of Asia Pacific Immunosuppressive Drugs Market
11.11.1. Increasing Incidence of Autoimmune and Inflammatory Diseases
11.11.2. Rising Disposable Income
12. Latin America Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Immunosuppressive Drugs Market Size and Forecast by Country
12.2.1. Developing healthcare infrastructure
12.3. Latin America Immunosuppressive Drugs Market Size and Forecast by Drug Class
12.3.1. Antibodies was the largest revenue grossing subsegment
12.4. Latin America Immunosuppressive Drugs Market Size and Forecast by Application
12.4.1. Organ transplant segment will witness fastest growth rate
12.5. Latin America Immunosuppressive Drugs Market Size and Forecast by Route of Administration
12.5.1. Oral Drugs segment projected to dominate the market during the forecast period 2020-2030
12.6. Latin America Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
12.6.1. Retail pharmacies segment accounted for significant revenue share
12.7. Brazil Immunosuppressive Drugs Market
12.7.1.1. Growing Disposable Income
12.7.1.2. Rapidly Improving Healthcare Infrastructure
12.8. Mexico Immunosuppressive Drugs Market
12.8.1.1. Affordable Treatments Option for Organ Transplant
12.8.1.2. Government Initiatives That Aim at Providing Better Healthcare Facilities
12.9. Rest of Latin America Immunosuppressive Drugs Market
12.9.1.1. Growing Burden of Autoimmune Diseases
12.9.1.2. Availability of Skilled and Inexpensive Workforce
13. MEA Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Immunosuppressive Drugs Market Size and Forecast by Country
13.2.1. Developing Healthcare Infrastructure
13.3. MEA Immunosuppressive Drugs Market Size and Forecast by Drug Class
13.3.1. Corticosteroids Segment Expected to Show Lucrative Growth Rate
13.4. MEA Immunosuppressive Drugs Market Size and Forecast by Application
13.4.1. Organ Transplant Segment Will Witness Fastest Growth Rate
13.5. MEA Immunosuppressive Drugs Market Size and Forecast by Route of Administration
13.5.1. Rising Adoption of Oral Drugs For the Treatment of Patients With Organ Transplant
13.6. MEA Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
13.6.1. Hospital Pharmacies Dominated the Market
13.7. Saudi Arabia Immunosuppressive Drugs Market
13.7.1.1. Presence of huge growth opportunities
13.7.1.2. Introduction of the Medical Aid Schemes Bill, National Health Insurance Bill, and introduction of new regulator for medicines
13.8. South Africa Immunosuppressive Drugs Market
13.8.1.1. Rising focus of pharmaceutical & biotechnology companies in this region
13.8.1.2. An emerging economy
13.9. Rest of MEA Immunosuppressive Drugs Market
13.9.1.1. Developing Healthcare Infrastructure
13.9.1.2. Rising Prevalence of Chronic Autoimmune Diseases
14. Companies in the Immunosuppressive Drugs Market
14.1. F. Hoffmann-La Roche AG
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2020)
14.1.3.1. Net Revenue ($mn), 2015-2019
14.1.3.2. Segment Revenue Share, 2019
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2020)
14.2. GlaxoSmithKline Plc
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Segment Revenue Share, 2019
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2020)
14.3. Johnson and Johnson
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Segment Revenue Share, 2019
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2020)
14.4. Novartis AG
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Segment Revenue Share, 2019
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2020)
14.5. Sanofi SA
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Segment Revenue Share, 2019
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2020)
14.6. Eli Lilly and Company
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Segment Revenue Share, 2019
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2020)
14.7. AbbVie Inc.
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Segment Revenue Share, 2019
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2020)
14.8. Amgen Inc.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Segment Revenue Share, 2019
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2020)
14.9. Bristol Myers Squibb Company
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Segment Revenue Share, 2019
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2020)
14.10. Astellas Pharma Inc.
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Segment Revenue Share, 2019
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.11. Other Notable Players
15. Conclusion
16. Glossary

List of Tables
Table 1 Global Immunosuppressive Drugs Market, 2020-2030 (US$ billion, CAGR %)
Table 2 Prevalence of Autoimmune Diseases, 2020
Table 3 Prevalence of Autoimmune Diseases, 2020
Table 4 Immunosuppressant Drugs: Average Cost per Set Period of Time by Dose
Table 5 Total R&D Investment by Leading Players
Table 6 Major M&A and Collaborations: Immunosuppressive Drugs Market
Table 7 Global Immunosuppressive Drugs Market Forecast by Drug Class, 2020-2030 (US$ billion, AGR %, CAGR %)
Table 8 “V” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 9 “U” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 10 “W” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 11 “L” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 12 Global Immunosuppressive Drugs Market for Antibodies Segment: Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 13 “V” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 14 “U” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 15 “W” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 16 “L” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
Table 17 Global Immunosuppressive Drugs Market for Calcineurin Inhibitor Segment: Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR %)



★調査レポート[免疫抑制薬の世界市場2020-2030] (コード:VGA20DE022)販売に関する免責事項を必ずご確認ください。
★調査レポート[免疫抑制薬の世界市場2020-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆